Nektar Therapeutics News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

04.11.24	Nektar To Sell Manufacturing Facility In Alabama, Reagent Supply Business To Ampersand (RTTNews)
08.08.24	Nektar Therapeutics Q2 Loss Misses Estimates (RTTNews)
12.06.24	Nektar Presents Positive Preclinical Data On TNFR2 For Treatment Of Inflammatory Disease (RTTNews)
09.05.24	Nektar Therapeutics Q1 Loss Drops In Line With Estimates (RTTNews)
04.03.24	Nektar Therapeutics Q4 Loss decreases, but misses estimates (RTTNews)
04.03.24	Nektar Therapeutics Announces $30 Mln Private Placement Financing With TCGX; Stock Up In Premarket (RTTNews)
12.12.23	Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting (PR Newswire)
07.11.23	Nektar Therapeutics Q3 Loss decreases, but misses estimates (RTTNews)
07.11.23	Nektar Therapeutics Reports Third Quarter 2023 Financial Results (PR Newswire)
31.10.23	Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets (PR Newswire)
13.10.23	Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress (PR Newswire)
02.10.23	Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy (PR Newswire)
27.09.23	Nektar, Cellular Biomedicine Enter New Clinical Study Collaboration (RTTNews)
27.09.23	Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer (PR Newswire)
13.09.23	Nektar Therapeutics Reports Promising Data From Phase 1b Study Of Rezpegaldesleukin (RTTNews)
13.09.23	Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis (PR Newswire)
07.09.23	Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th (PR Newswire)
08.08.23	Nektar Therapeutics Q2 Loss decreases, beats estimates (RTTNews)
08.08.23	Nektar Therapeutics Reports Second Quarter 2023 Financial Results (PR Newswire)
07.08.23	Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company (PR Newswire)
02.08.23	Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets (PR Newswire)
13.06.23	Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference (PR Newswire)
09.05.23	Nektar Therapeutics Q1 Loss increases, misses estimates (RTTNews)
09.05.23	Nektar Therapeutics Reports First Quarter 2023 Financial Results (PR Newswire)
27.04.23	Nektar Regains Full Rights Of REZPEG From Eli Lilly, Plans To Initiate Phase 2b Study (RTTNews)
27.04.23	Nektar Therapeutics Announces It Will Regain Full Rights to Rezpegaldesleukin (REZPEG, NKTR-358), a Novel, First-in-Class Selective Regulatory T-cell (Treg) Therapy in Clinical Development (PR Newswire)
17.04.23	Nektar Therapeutics Announces Strategic Reprioritization and Cost Restructuring Plan (PR Newswire)
29.03.23	Crane Set to Join S&P MidCap 400; PacWest Bancorp to Join S&P SmallCap 600 (PR Newswire)
12.03.23	Nektar Therapeutics Issues Statement Confirming That It Does Not Hold Any Cash Deposits or Securities at Silicon Valley Bank (PR Newswire)
01.03.23	Nektar Therapeutics Q4 Loss decreases, beats estimates (RTTNews)
28.02.23	Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results (PR Newswire)
23.02.23	Nektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus (PR Newswire)
04.01.23	Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA (PR Newswire)
12.12.22	Nektar Announces Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting (PR Newswire)
05.12.22	Nektar Therapeutics to Host Investor & Analyst Event on December 12th (PR Newswire)
14.11.22	Pre-market Movers: OPNT, MOR, TRMR, TOI, NKTR… (RTTNews)
10.11.22	Nektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Program, NKTR-288, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting (PR Newswire)
09.11.22	Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, a Novel Polymer-conjugated Human IL-15, Improves Efficacy of CD19-targeted CAR-T Cell Im... (PR Newswire)
03.11.22	Nektar Therapeutics Q3 Loss decreases, beats estimates (RTTNews)
03.11.22	Nektar Therapeutics Reports Third Quarter 2022 Financial Results (PR Newswire)
26.10.22	Nektar to Announce Financial Results for the Third Quarter 2022 on Thursday, November 3, 2022, After Close of U.S.-Based Financial Markets (PR Newswire)
11.10.22	Form 8.3 - The Vanguard Group, Inc.: Nektar Therapeutics, Inc (EQS Group)
11.10.22	Nektar Therapeutics, PureTech End Merger Talks - Quick Facts (RTTNews)
10.10.22	Form 8.3 - The Vanguard Group, Inc.: Nektar Therapeutics, Inc (EQS Group)
07.09.22	Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851) in Patients with Atopic Dermatitis and Psoriasis from Two Separate Clinical Studies at 2022 European Academy of Dermatology (EAD... (PR Newswire)
16.08.22	Nektar Therapeutics: Preclinical Findings Support Clinical Development Program For NKTR-255 (RTTNews)
16.08.22	Nektar and Collaborators Announce Preclinical Publication of Data for NKTR-255 and its Observed Improvement of NK Cell Function in Multiple Myeloma (PR Newswire)
04.08.22	Nektar Therapeutics Q2 Loss increases, but beats estimates (RTTNews)
04.08.22	Nektar Therapeutics Reports Second Quarter 2022 Financial Results (PR Newswire)
27.07.22	Nektar to Announce Financial Results for the Second Quarter 2022 on Thursday, August 4, 2022, After Close of U.S.-Based Financial Markets (PR Newswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

15.11.24		Schwacher Handel in New York: NASDAQ Composite verbucht zum Handelsende Abschläge
15.11.24		Zurückhaltung in New York: NASDAQ Composite verbucht nachmittags Verluste
15.11.24		NASDAQ Composite aktuell: NASDAQ Composite mittags mit Abgaben
04.11.24		Verluste in New York: NASDAQ Composite beendet die Montagssitzung mit Verlusten
04.11.24		Freundlicher Handel: NASDAQ Composite am Montagnachmittag auf grünem Terrain
04.11.24		Börse New York in Rot: NASDAQ Composite gibt am Mittag nach
04.11.24		Verluste in New York: NASDAQ Composite beginnt Montagshandel mit Verlusten
29.10.24		NASDAQ Composite-Handel aktuell: NASDAQ Composite letztendlich auf grünem Terrain